Imidazole → 13,13,14,14-Tetramethyl-3,6,9,12-tetraoxa-13-silapentadecan-1-ol
反応式
[C:1]([Si:5]([CH3:14])([CH3:13])[O:6][CH2:7][CH2:8][O:9][CH:10](O)[CH3:11])([CH3:4])([CH3:3])[CH3:2].[CH2:15]([OH:27])[CH2:16][O:17][CH2:18][CH2:19][O:20]CCOCCO.CC([Si](Cl)(C)C)(C)C.N1C=CN=C1>CN(C=O)C>[C:1]([Si:5]([CH3:14])([CH3:13])[O:6][CH2:7][CH2:8][O:9][CH2:10][CH2:11][O:27][CH2:15][CH2:16][O:17][CH2:18][CH2:19][OH:20])([CH3:4])([CH3:3])[CH3:2]参加物
6
実験手順
Compound 28b was prepared according to the procedure described hereinabove for Compound 28a, using tetraethylene glycol (6 grams, 30 mmol), TBDMSCl (3 grams, 20 mmol), and imidazole (1.4 grams, 20 mmol) in DMF (24 ml), yielding 3.79 grams of the product (41% yield).
出典と根拠
- ORDレコード
- ord-0c06a23abbe544bf87e80226b614379a
- 出典データセット
- uspto-grants-2013_06
- 特許番号
- US08461166B2
反応ノート
読み込み中…